Mechanism of Action: Volasertib (BI 6727)
Volasertib (BI 6727) is a potent and selective inhibitor of PLK1 in vitro that is currently being evaluated for its therapeutic potential to target the cell cycle.
Volasertib (BI 6727) is a potent and selective inhibitor of PLK1 in vitro that is currently being evaluated for its therapeutic potential to target the cell cycle. Volasertib selectively binds to the ATP binding pocket of PLK1, thereby inhibiting its ability to regulate cell division, and resulting in cell cycle arrest.
The FDA has granted a Breakthrough Therapy designation to volasertib in combination with low-dose cytarabine (LDAC) for its potential as a treatment for patients with untreated acute myeloid leukemia (AML) who are ineligible for intensive remission induction therapy.
Read more on the Breakthrough Therapy designation >>
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
